NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee approved inducement option grants covering 18,000 ordinary shares to one non-executive new hire under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $37.00, equal to the Nasdaq closing price on the grant date of November 3, 2025. Vesting occurs over four years: 25% on the one-year anniversary of the vesting commencement date, then the remainder in 36 equal monthly installments, subject to continued service. Grants are subject to the 2024 Inducement Plan and the related option award agreement.

NAARDEN, The Netherlands and MIAMI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 18,000 of NewAmsterdam’s ordinary shares to one non-executive new hire. The share options were granted as an inducement material to the employee’s acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $37.00, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on, November 3, 2025, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to the employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

FAQ

What did NewAmsterdam (NAMS) announce on November 7, 2025?

NewAmsterdam announced inducement option grants covering 18,000 ordinary shares to one non-executive new hire.

What is the exercise price and grant date for the NAMS inducement options?

The exercise price is $37.00, equal to the Nasdaq closing price on the grant date of November 3, 2025.

How do the NAMS inducement options vest?

Options vest over four years: 25% at the one-year anniversary, then the balance in 36 equal monthly installments, subject to continued service.

Under which plan and Nasdaq rule were the NAMS inducement options granted?

The options were granted under the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement grants in the NAMS announcement?

The announcement states the grants were made to one non-executive new hire.